Drugs Made in America Acquisition Corp.

Introduction

Drugs Made in America Acquisition Corp. (Nasdaq: DMAA) is a Cayman Islands–incorporated blank check company formed for the purpose of effecting a business combination in the pharmaceutical industry. The Company seeks to on‐shore end-to-end production, manufacturing, and distribution of critical medications, aiming to create jobs, mitigate national security risks, and ensure a resilient U.S. drug supply chain.

Corporate Structure and Experience

• Chief Executive Officer & Executive Chair: Lynn Stockwell
• Advisory Team
  • Charles C. Conaway, former President of CVS Corporation and Chairman of The Sabre Group
  • Paul J. Mastronardi, third-generation greenhouse grower and distributor
  • Edward A. Robinson, former CEO of BMW Financial Services N.A.
• Corporate Status: The Company does not have operating subsidiaries; it intends to complete a merger, share exchange, or similar combination with one or more target businesses in the pharmaceutical sector.

Recent Developments

• February 18, 2025: The underwriter exercised the full over‐allotment option, increasing the total number of units sold to 23 million, resulting in gross proceeds of $230 million.
• February 20, 2025: The Company announced that effective February 25, 2025, holders may elect to separate units into ordinary shares (DMAA) and rights (DMAAR).
• February 24, 2025: An advisory team was formed under CEO Lynn Stockwell to identify and execute acquisition opportunities in U.S.-based pharmaceutical manufacturing.
• May 20, 2025: The Company filed Form 10-Q for the quarter ended March 31, 2025, reporting no significant operating revenues to date.

Financial and Strategic Analysis

• IPO Proceeds: $230 million gross, consisting of 23 million units sold at $10.00 per unit. Each unit comprises one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon consummation of a business combination.
• Cash Trust: The proceeds are held in trust pending the completion of an initial business combination.
• Strategic Focus
  • On-Shoring: The Company plans to invest in advanced domestic manufacturing technologies to reduce reliance on concentrated offshore production for pharmaceuticals.
  • Advisory Expertise: The Company intends to leverage the industry experience of its advisory team to identify and negotiate potential acquisition targets.
• Regulatory and Reporting: A notification of inability to timely file the quarterly report was resolved with the May 20, 2025, filing of Form 10-Q.

Market Position and Industry Context

Metric	Value
Ticker	DMAA
Exchange	Nasdaq Global
Share Price (USD)	10.13
Price Change (%)	0.00
Volume (May 23, 2025)	100,103
Average Volume	203
Volume Rate	+9,999.99%

As a special purpose acquisition company, DMAA is among several SPACs targeting pharmaceutical assets. Its focus on domestic drug supply chains aligns with increasing regulatory and investor interest in addressing vulnerabilities in drug supply and supporting U.S. manufacturing.

tl;dr

• On February 18, 2025, DMAA’s underwriter fully exercised its over-allotment option, bringing total IPO proceeds to $230 million.
• Beginning February 25, 2025, ordinary shares (DMAA) and rights (DMAAR) began separate trading on Nasdaq.
• On February 24, 2025, the Company formed an advisory team led by industry veterans Charles Conaway, Paul Mastronardi, and Edward Robinson to source U.S. pharmaceutical acquisition targets.
• The Company filed its Form 10-Q on May 20, 2025, with maximum trust proceeds held and no operating revenues reported until completion of an initial business combination.